Condition: Neuroendocrine Tumors · Neuroendocrine Neoplasms · Sponsor: Shanghai Zhongshan Hospital
This is a prospective, multicenter, phase 4, single-arm study designed to evaluate the effectiveness and safety of surufatinib in adult patients with advanced neuroendocrine neoplasms (NENs) treated in routine clinical practice. Approximately 350 patients with histologically or cytologically confirmed advanced NENs and at least one measurable lesion (RECIST 1.1) will receive oral surufatinib, either as monotherapy (300 mg once daily in 4-week cycles) or in combination regimens (250 mg once daily), according to the treating physician's judgment and protocol guidance. Participants will be followed with regular imaging, laboratory tests, cardiac assessments, and patient-reported outcome questionnaires to monitor tumor response, side effects, quality of life, and treatment adherence. The primary outcomes include progression-free survival, objective response rate, disease control rate, and overall survival; safety will be assessed by the type, frequency, and severity of adverse events. The findings are expected to inform standardized, evidence-based use of surufatinib and help optimize individualized treatment strategies for patients with advanced NENs in the real-world setting.
This description comes directly from the study's public registry record.
Wenquan Wang, M.D. Ph.D · +86 21 31587861 · wang.wenquan@zs-hospital.sh.cn
Xu Han, M.D. Ph.D · +86 21 31587861 · han.xu1@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Huadong Hospital Affiliated to Fudan University | Shanghai, China | Recruiting |
| Huashan Hospital Affiliated to Fudan University | Shanghai, China | Recruiting |
| Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine | Shanghai, China | Recruiting |
| Shanghai General Hospital shanghai jiao tong university school of medicine | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07272512